Stoke Therapeutics, Inc. STOK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Global Development Activity | $19.89M— | $17.49M— | —— | —— | —— | |
| IP License | $0— | $150.78M— | —— | —— | —— | |
| Operating Expenses by Product | ||||||
| ADOA | -$6.81M+1.1% | -$6.16M+16.9% | -$5.85M+28.2% | -$5.68M+35.1% | -$6.89M+12.0% | |
| MECP2 | $184K+119% | $37K+103% | -$209K+80.4% | -$516K+48.0% | -$970K+1.5% | |
| Other External Program Costs | -$10.19M-19.0% | -$8.84M-0.7% | -$8.84M-6.8% | -$8.35M+7.5% | -$8.56M+9.3% | |
| Other Non Program Costs Research And Development | -$6.42M-21.8% | -$6.15M-15.5% | -$5.54M-1.6% | -$5.42M-12.8% | -$5.27M-23.5% | |
| Payroll And Other Personnel Costs Research And Development | -$56.81M-41.0% | -$51.71M-38.1% | -$45.71M-30.3% | -$42.76M-27.9% | -$40.3M-24.5% | |
| SYNGAP1 | -$3.74M-171% | -$3.33M-153% | -$2.47M-133% | -$1.96M-145% | -$1.38M-96.9% | |
| Zorevunersen | -$74.01M-81.0% | -$71.83M-125% | -$58.34M-89.5% | -$44.96M-49.5% | -$40.89M-37.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stoke Therapeutics, Inc. break its business down?
- Stoke Therapeutics, Inc. (STOK) reports revenue by product across 4 parts — Global Development Activity, IP License, License and Service. Each is extracted from the segment footnotes and tracked over time.
- Where does Stoke Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stoke Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.